Adverum Biotechnologies Stock (NASDAQ: ADVM)

Adverum Biotechnologies (NASDAQ:ADVM) Stock, Quote.Headers.trade-ideas

Adverum Biotechnologies

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

wall street chart shutter2

Long Ideas

News

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ADVM

TCBI

Around $88M Bet On NextDecade? Check Out These 3 Stocks Insiders Are Buying

Image44

Intraday Update

APPN

More Than $10M Bet On Appian? Check Out These 3 Stocks Insiders Are Buying

Biotech

Earnings

Analyst Ratings

General

MEDP

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Adverum Biotechnologies (NASDAQ: ADVM) been one of those stocks this year?

Is Adverum Biotechnologies Stock Outpacing Its Medical Peers This Year?

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies Inc

Candidates are invited to explore full- and part-time seasonal opportunities supporting Macy's, Inc.'s portfolio of nameplates, including Macy's, Bloomingdale's and Bluemercury
Holiday hiring events will take place nationwide at all stores and distribution centers throughout the season, with the first on Thursday, September 26
Macy's, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) today announced plans to hire more than 31,500 full- and part-time seasonal positions this upcoming holiday season at its Macy's, Bloomingdale's and Bluemercury stores, as well as its distribution centers. Macy's, Inc. offers several convenient hiring experiences for candidates including an online application process that takes as little as five minutes, with most job offers made within 48 hours. Additionally, the company is holding four nationwide in-person holiday hiring events at all stores and supply chain locations. Times may vary by location.
<ul>
<li>September 26</li>
<li>October 24</li>
<li>November 21</li>
<li>December 4</li>
</ul>

Management

Macy's Gears Up To Hire For More Than 31,500 Seasonal Positions; Holiday Hiring Events Will Take Place Nationwide At All Stores And Distribution Centers Throughout The Season, With The First On Thursday, September 26

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNGGF">Cann Gr</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNGGF#OTC">CNGGF</a>) shares closed up 346.42% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed up 53.73% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 45.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 35.97% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed up 24.59% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 11.11% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 9.56% at $1.39</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 9.30% at $0.26</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed up 8.50% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 7.22% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/GENE">Genetic Technologies</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) shares closed up 5.53% at $0.81</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 4.80% at $51.70</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed up 4.52% at $11.96</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 3.98% at $0.05</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 70.00% at $0.0006</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed down 29.89% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 26.78% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 18.02% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 12.82% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 4.03% at $3.01</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 3.53% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 3.19% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed down 3.11% at $11.06</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 3.04% at $0.04</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Movers

BLGVF

BMMJ

CBDY

CNGGF

CNPOF

CNTMF

CPHRF

CRBP

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

FFNTF

FUAPF

GENE

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

LVRLF

MGWFF

NWVCF

RMHB

SOLCF

UGRO

XXII

Bullish Sentiment Across The Cannabis Space - Check Full Movers For September 19, 2024

Buybacks

FANG

Diamondback Energy Board Approved Increasing Total Authorized Repurchases Under Co's Existing Common Stock Repurchase Program To $6B

FedEx Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) reported financial results for the first quarter of fiscal 2025 after the market close on Thursday. Here&#8217;s a look at the <a href="https://www.benzinga.com/pressreleases/24/09/b40947326/fedex-reports-first-quarter-diluted-eps-of-3-21-and-adjusted-diluted-eps-of-3-60">key metrics from the quarter</a>.
Q1 Earnings: FedEx reported first-quarter revenue of $21.6 billion, missing analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $21.955 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported first-quarter adjusted earnings of $3.60 per share, missing analyst estimates of $4.80 per share.
FedEx said its first-quarter&nbsp;results were negatively affected by a mix shift, which reduced demand for priority services, increased demand for deferred services and constrained yield growth. The quarter was also impacted by higher operating expenses and one fewer operating day in the quarter.
Federal Express operating results fell during the quarter due to lower U.S. domestic priority package volume. Increased wage and purchased transportation rates also negatively impacted operating results. FedEx Freight operating results decreased during the quarter due to a decline in weight per shipment and reduced priority shipments.
FedEx noted it completed a $1 billion accelerated <a href="https://www.benzinga.com/news/buybacks">buyback</a> during the quarter. The company expects to repurchase an additional $1.5 billion of its common stock during fiscal 2025. As of Aug. 31, $4.1 billion remained on the buyback program. FedEx said it ended the quarter with $5.9 billion in cash on hand.
&#8220;Despite a challenging quarter, we remain focused on transforming our network, improving our efficiency, lowering our cost-to-serve, and enhancing our ability to adapt with speed to evolving market dynamics,&#8221; said&nbsp;Raj Subramaniam, president and CEO of FedEx.
&#8220;Overall, I remain confident in the value-creation opportunities ahead as we focus on reducing our structural cost, growing revenue profitably, and leveraging the insights from our vast collection of data as we continue to build the world&#8217;s most flexible, efficient and intelligent network.&#8221;
See Also: <a href="https://www.benzinga.com/24/09/40932449/darden-restaurants-fedex-and-3-stocks-to-watch-heading-into-thursday">Darden Restaurants, FedEx And 3 Stocks To Watch Thursday</a>
Outlook: FedEx revised its full-year outlook lower. The company now sees full-year 2025 revenue growing in the low single-digit range, versus its prior outlook of revenue growth in the low-to-mid single-digits. 
The company also lowered its full-year earnings forecast from a range of $18.25 to $20.25 per share to a new range of $17.90 to $18.90 per share.
Management will hold a conference call to discuss these quarterly results at 5:30 p.m. ET.
FDX Price Action: <a href="http://benzinga.com/quote/fdx">FedEx shares</a> were down 8.94% in after hours, trading at $273.55 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Shutterstock.

Guidance

After-Hours Center

FedEx Q1 Earnings: Revenue Miss, EPS Miss, Lowered Guidance — 'Challenging Quarter'

The European Commission has officially <a href="https://citizens-initiative.europa.eu/initiatives/details/2024/000011_en">registered</a> the PsychedeliCare initiative, which advocates for establishing a transnational legal framework for <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted treatments</a> for mental health disorders. As Green Market Report <a href="https://www.greenmarketreport.com/eu-initiative-begins-bid-to-open-access-to-psychedelic-therapies/">outlined</a>, this European Citizens&#8217; Initiative aims to create progressive regulations around psychedelic therapies across the E.U.
<h3 class="wp-block-heading">Aiming For Legal Framework On Psychedelic Therapies</h3>
"We are scientists, medical doctors, therapists, neuroscience researchers, creative and marketing professionals, artists, policy experts, human and civil rights activists, spiritual practitioners and educators. Together, united behind science and knowledge of EU laws, the goal of our initiative is to enable Europeans to access safe, regulated and conscientious Psychedelic-Assisted Therapy", the group states on its website.
The PsychedeliCare initiative seeks to promote expert consensus on the standards of care in psychedelic-assisted therapy, covering therapist training, ethical guidelines and safety measures. It also calls for E.U.-funded research to strengthen the evidence on the safety and efficacy of psychedelic treatments for mental health conditions.
<h3 class="wp-block-heading">Economic Impact And Unmet Needs</h3>
Organizers of the initiative highlighted the high economic toll of mental health disorders in the E.U., <a href="https://www.oecd.org/en/topics/sub-issues/mental-health.html">estimated</a> at $669.4 billion annually by the Organisation for Economic Co-operation and Development. With 50% of psychiatric patients not responding to current treatments, the initiative underscores the need for innovative approaches like psychedelic therapies. The E.U. has approved just one psychiatric treatment in the last three years, compared to 68 new oncology treatments.
<h3 class="wp-block-heading">Global Momentum For Psychedelics</h3>
The PsychedeliCare organizers point to international developments, including the U.S. FDA&#8217;s <a href="https://www.benzinga.com/topic/fda-breakthrough-designation">breakthrough therapy designations</a> for <a href="https://www.benzinga.com/topic/mdma-assisted-therapy">MDMA</a> and <a href="https://www.benzinga.com/topic/psilocybin-assisted-therapy">psilocybin</a>, as well as Canada&#8217;s and <a href="https://www.benzinga.com/general/biotech/24/01/36770123/australian-psychiatrists-provide-first-psychedelic-assisted-medical-treatments-in-50-years">Australia's</a> advancements in allowing psychedelic-assisted therapies for anxiety and depression. The initiative hopes to encourage the E.U. to follow suit and incentivize mental health R&amp;D.
<h3 class="wp-block-heading">Signature Collection: The Next Step</h3>
To move forward, PsychedeliCare must collect 1 million signatures within a year, meeting the minimum thresholds in at least seven E.U. countries. If successful, the European Commission will be required to respond and consider potential legal action. The initiative also seeks to position Europe as a global hub for psychedelic therapy innovation.
Cover image made with AI

Psychedelics

Eurozone

European Initiative Pushes For Psychedelic Therapy Reform To Address $669B Mental Health Problem: The Goal Is To Gather 1 Million Signatures

In the latest chapter of Alabama&#8217;s medical cannabis rollout saga, local cannabis company <a href="https://www.benzinga.com/topic/alabama-always-llc">Alabama Always, LLC</a> has filed a lawsuit against the Alabama Medical Cannabis Commission (AMCC), seeking a partial summary judgment and a permanent injunction. <a href="https://www.alreporter.com/2024/09/18/new-amcc-lawsuit-chaos-delays-and-broken-rules-in-alabamas-cannabis-rollout/">According</a> to Alabama Political Reporter, the lawsuit accuses the AMCC of violating the Alabama Administrative Procedure Act (AAPA), citing numerous procedural failures that have derailed the state's medical cannabis program, leaving thousands of patients in limbo.
At the core of the legal battle are the Commission's <a href="https://www.benzinga.com/markets/cannabis/23/12/36115077/cannabis-licensing-saga-continues-in-alabama-troubled-marijuana-regulator-hit-with-new-lawsuit">controversial decisions on integrated license awards</a> and denials in 2023. Alabama Always argues that these decisions were not only flawed but illegal, claiming the AMCC bypassed mandatory contested case hearings and violated its own blind scoring rules.
<h3 class="wp-block-heading">Key Allegations Against The AMCC</h3>
Alabama Always alleges that the AMCC&#8217;s reliance on an "investigative hearing" process undermines transparency and due process. The company contends that the Commission's refusal to follow the AAPA and its insistence on continuing with its invalid hearing practices will only further delay the already troubled rollout of medical cannabis.
In addition to these claims, the lawsuit targets the AMCC's adoption of an "emergency rule" in October 2023, which the plaintiff says was implemented without the required public notice or comment. According to Alabama Always, the rule was designed to fast-track the licensing process at the expense of transparency and accountability.
Attorney Will Somerville, representing Alabama Always, emphasized the Commission's failure to comply with state law. &#8220;They have never explained why some people got licenses and some didn't. Most egregiously to me, they didn't explain how they thought some people could do the job of producing medical cannabis while others couldn't," Somerville said, urging the court to force the AMCC to start fresh and adhere to legal requirements.
<h3 class="wp-block-heading">Legal Delays Impact Patients And Businesses</h3>
The lawsuit isn&#8217;t just a bureaucratic battle; real lives are at stake. Patients in Alabama waiting for access to <a href="https://www.benzinga.com/topic/medical-cannabis">medical cannabis</a> continue to suffer as the Commission's administrative failures drag on. Observers have criticized the AMCC for prioritizing self-preservation over fixing the flawed process.
As the legal process unfolds, Judge James H. Anderson will determine whether Alabama Always's motion will reset the entire licensing process, or if the AMCC will continue its current practices, further entrenching uncertainty for the patients and businesses involved.
Cover image made with AI

Alabama Marijuana Company Sues Medical Cannabis Commission Over Licensing Chaos, Seeks Program Overhaul As Patients Remain In Limbo

KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>)&nbsp;announced today that KTJV, a KBR and Technip Energies joint venture, has been selected by Lake Charles&nbsp;LNG Export Company, a subsidiary of Energy Transfer LP, for its Lake Charles LNG transformation project.
Under the terms of the agreement, KTJV will provide high-end engineering, procurement, construction management, construction, commissioning, startup and other related services, subject to Lake Charles LNG's decision to issue a notice to proceed for the project.
The project would transform Energy Transfer's existing import facility into a world-class LNG export facility to meet the world's growing LNG and energy security demands. This conversion would include the delivery of three liquefaction trains and modifications to existing storage and dock facilities designed to enable the export of 16.45 metric tons per annum of LNG.

Contracts

KBR Announces KTJV, A KBR And Technip Energies Joint Venture, Has Been Selected By Lake Charles LNG Export Company, A Subsidiary Of Energy Transfer LP, For Its Lake Charles LNG Transformation Project

WIIM

MLKN

MillerKnoll shares are trading lower after the company reported worse-than-expected Q1 financial results and issued Q2 EPS guidance below estimates.

SBGI

Sinclair Updates Q3 Political Advertising Revenue Guidance From $113M-$128M To $140M-$145M; Now Sees Q3 Local Media Advertising Revenue $425M-$438M, Up From Prior Expectation Of $401M-$428M

On Friday, September 13, Washington D.C. authorities shut down Green Cloud Shop, an unlicensed cannabis business, as part of a broader crackdown on illegal cannabis operations.
The Alcoholic Beverage and Cannabis Administration (ABCA), alongside the Metropolitan Police Department (MPD), <a href="https://abca.dc.gov/release/abca-shutters-illegally-operating-cannabis-business#gsc.tab=0">padlocked</a> the shop. The owner, a 49-year-old man, was arrested and charged with Possession with Intent to Distribute and Operating a Business After Certificate of Authority had been revoked.
This measure came in the context of an ongoing conflict with unregulated &#8220;gift economy&#8221; cannabis shops, which were tolerated in the past but are now being pushed to adapt to regulations, <a href="https://www.axios.com/local/washington-dc/2024/09/18/marijuana-dispensary-gifting-shops-crackdown">reported</a> Axios.
<h3 class="wp-block-heading">Say Goodbye To D.C.&#8217;s Cannabis Gifting Economy</h3>
Cannabis gifting shops in D.C. have long used a loophole by "gifting" marijuana when customers purchase other products. This allowed them to bypass laws against recreational cannabis sales, in the context of the tricky legal situation affecting Washington D.C. cannabis.
However, city officials are now stepping up enforcement. The more than 100 unlicensed shops that are currently operating are seen as a major threat to the legal medical cannabis market.
The crackdown comes after the D.C. Council green-lit an emergency bill to give city officials the authority to impose penalties on unlicensed cannabis stores <a href="https://www.benzinga.com/markets/cannabis/24/01/36597430/new-emergency-law-empowers-authorities-to-crack-down-on-cannabis-gifting-shops-in-d-c">earlier this year</a>. D.C. lawmakers, including progressive members, are backing this crackdown due to concerns about crime around all-cash businesses and the proximity of some shops to schools and daycare facilities.
<ul>
<li>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/03/37896144/washington-state-gov-signs-bill-eliminating-medical-marijuana-tax-iowa-to-add-25-excise-tax-on-h">Washington State Gov. Signs Bill Eliminating Medical Marijuana Tax, Iowa To Add 25% Excise Tax On Hemp &amp; More</a></li>
</ul>
<h3 class="wp-block-heading">The Latest Developments In D.C.</h3>
Green Cloud Shop's closure is part of a new wave of enforcement following the Medical Cannabis Conditional License and Unlicensed Establishment Closure Clarification Emergency Amendment Act of 2024. This law, enacted in July, grants the ABCA enhanced authority to close illegal businesses.
Green Cloud is the second illicit cannabis business closed by ABCA since the new law went into effect. 
Curiously, authorities reported padlocking the access to the store. This echoes New York&#8217;s <a href="https://www.benzinga.com/markets/cannabis/24/09/40910485/is-mayor-adams-crackdown-on-illegal-cannabis-working-nyc-council-weighs-in-after-1-000-store-clo">special operation</a> that cracked down on illicit cannabis during the first few months of the year.
In addition to the closures, the ABCA has issued 23 cease-and-desist orders and 79 warning letters to unlicensed cannabis businesses. Many shops, however, continue operating, with only a few being forced to shut down.
But still, property owners of illicit cannabis shops could face a $10,000 fine if they fail to comply with the ABCA's closure orders.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">The Struggle Of Legal D.C. Cannabis Dispensaries</h3>
The crackdown comes at a crucial time for D.C.'s legal <a href="https://www.benzinga.com/markets/cannabis/24/06/39262441/washington-provides-tax-break-for-medical-cannabis-users-but-is-it-enough">medical cannabis </a>market, which has been <a href="https://www.benzinga.com/markets/cannabis/24/07/39937544/medical-marijuana-market-in-d-c-at-risk-of-perishing-affected-business-owner-explains">struggling to compete</a> with unlicensed operators. 
Adding to the pressure, D.C. dispensaries face stiff competition from Maryland's legal recreational market, where prices are often lower. Since January 2024, D.C.'s legal market has been in a steep decline, selling less than 400 pounds of flower per month. 
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/06/39262441/washington-provides-tax-break-for-medical-cannabis-users-but-is-it-enough">Washington Provides Tax Break For Medical Cannabis Users, But Is It Enough?</a></li>
</ul>
Cover: Benzinga edit based on Washarapol D BinYo Jundang and Anna Lowe via Pixels

Government

Regulations

Politics

D.C. Continues Crackdown On Cannabis Gifting Shops: One Arrested, Store Padlocked, Although Many More Remain Open

Alternus Clean Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALCE#NASDAQ">ALCE</a>) ("Alternus" or the "Company"), a leading utility-scale transatlantic, clean energy independent power producer (IPP), has terminated its MIPSA with C2 Taiyo Fund I, LLP to acquire approximately 80MWp solar installations across 8 U.S. states, originally announced on May 1, 2024, due to seller's failure to meet the required closing conditions and fundamental changes in the portfolio of assets planned to be acquired.

ALCE

Alternus Clean Energy Has Terminated Its MIPSA With C2 Taiyo Fund I, LLP To Acquire ~80MWp Solar Installations Across 8 U.S. States, Originally Announced On May 1, 2024, Due To Seller's Failure To Meet The Required Closing Conditions And Fundamental Changes In The Portfolio Of Assets Planned To Be Acquired

Nike shares are trading higher after the company announced Elliot Hill will take over as the new President and CEO. John Donahoe will retire from his position.

TechnipFMC Awarded Two Subsea Contracts By Petrobras For Brazil's Pre-Salt Fields; First Contract Is Between $250M-$500M And Second Is Between $75M-$250M

GNFT

CORRECTION: Genfit H1 2024 Adj. EPS €0.53; Revenues And Other Income €61.199M

Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) revealed 9 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 66% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $562,711, and 5 were calls, valued at $259,716.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $60.0 to $100.0 for Moderna during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of 2,026.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $60.0 to $100.0 over the last 30 days.
<h3>Moderna Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726777077_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$25.9</td>
<td>$24.35</td>
<td>$25.9</td>
<td>$90.00</td>
<td>$388.5K</td>
<td>1.9K</td>
<td style="text-align: right;">150</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$13.3</td>
<td>$13.25</td>
<td>$13.3</td>
<td>$70.00</td>
<td>$81.1K</td>
<td>108</td>
<td style="text-align: right;">123</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$31.0</td>
<td>$30.85</td>
<td>$31.0</td>
<td>$100.00</td>
<td>$65.1K</td>
<td>0</td>
<td style="text-align: right;">609</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$2.66</td>
<td>$2.65</td>
<td>$2.65</td>
<td>$60.00</td>
<td>$59.3K</td>
<td>1.6K</td>
<td style="text-align: right;">233</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.6</td>
<td>$3.55</td>
<td>$3.55</td>
<td>$80.00</td>
<td>$58.5K</td>
<td>702</td>
<td style="text-align: right;">536</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Following our analysis of the options activities associated with Moderna, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>Trading volume stands at 5,013,059, with MRNA's price down by -2.52%, positioned at $68.1.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 42 days.</li>
</ul>
<h3>What Analysts Are Saying About Moderna</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $82.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Sector Perform, setting a price target of $75. 
&#x2A; An analyst from RBC Capital has decided to maintain their Sector Perform rating on Moderna, which currently sits at a price target of $75. 
&#x2A; An analyst from Jefferies has revised its rating downward to Hold, adjusting the price target to $65. 
&#x2A; An analyst from HSBC upgraded its action to Hold with a price target of $82. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Moderna, targeting a price of $115. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

MRNA

Behind the Scenes of Moderna's Latest Options Trends

Offerings

KOPN

Kopin Corporation Announces Public Offering of Common Stock and Pre-Funded Warrants, Plans to Use Proceeds for Corporate Purposes and Potential Litigation Payments; Size Not Disclosed

Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) reported quarterly earnings of $0.57 per share. This is a 226.67 percent increase over losses of $(0.45) per share from the same period last year. The company reported $63.49 million in sales this quarter. This is a 281.83 percent increase over sales of $16.63 million the same period last year.

Genfit H1 EPS $0.57 Up From $(0.45) YoY, Sales $63.49M Up From $16.63M YoY (Converted To USD)

TIGO

Millicom International Cellular Appoints Maxime Lombardini As Interim Chair Of The Board

Nike Says Elliott Hill To Join Nike Board And Executive Committee

Cryptocurrency markets are trading 5.9% higher to $2.19 trillion as crypto short liquidations spiked to the highest level since Aug. 23.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$63,485.74</td>
<td>+5.3%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,467.60</td>
<td>+6.6%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$143.74</td>
<td>+10.8%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1062</td>
<td>+5%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.0000142</td>
<td>+6.3%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows a 1% drop in large transaction volume and a 5.7% decline in daily active addresses. However, exchanges netflows narrowed by 278.4%. With Bitcoin prices racing beyond the $61,000 mark, 88% of Bitcoin holders are in profit, while 12% are at breakeven.</li>
<li>Coinglass data shows 61,634 traders liquidated in the past 24 hours for $190.39 million, with short liquidations coming in at $117.6 million, the highest level since Aug. 23.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40943186/cybercriminals-busted-for-243m-crypto-heist-they-spent-hundreds-of-thousands-in-night-club">Cybercriminals Busted For $243M Crypto Heist: They Spent Hundreds Of Thousands In Night Clubs And On Luxury Gifts</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40942924/whats-going-on-with-coinbase-stock">What&#8217;s Going On With Coinbase Stock?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40944865/jade-city-to-democratize-access-to-50b-jade-market-with-tokenization-platform">Jade City To Democratize Access To $50B Jade Market With Tokenization Platform</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Popcat (SOL) (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">POPCAT</a>)</td>
<td>$0.8976</td>
<td>+28.2%</td>
</tr>
<tr>
<td>Sei (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SEI</a>)</td>
<td>$0.3344</td>
<td>+19.9%</td>
</tr>
<tr>
<td>Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>)</td>
<td>$1.77</td>
<td>+18.5%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin prices chasing the $63,000 mark, Cold Blooded Shiller predicts that if this move breaks to the upside, &#8220;expect this area to be a sweep with a fast response back.&#8221; He suggests keeping note of the $61,500 level.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If we get the LTF <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> correction I think the reaction around $61.5k will be important. If this move is going to break HTF structure to the upside I&#39;d expect this area to be a sweep with a fast response back. (The good ol&#39; V-reversal days) <a href="https://t.co/0nowzEJ8dL">pic.twitter.com/0nowzEJ8dL</a>
&mdash; Cold Blooded Shiller (@ColdBloodShill) <a href="https://twitter.com/ColdBloodShill/status/1836847538164363288?ref_src=twsrc%5Etfw">September 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<figcaption class="wp-element-caption">Crypto trader Scient <a href="https://x.com/Crypto_Scient/status/1836849315878256780">states</a> that this is that part of cycle where Bitcoin cools off, &#8220;does a bit of correction and altcoins take the lead.&#8221; However, after Bitcoin&#8217;s consolidation, it takes the lead again, makes the next leg higher and altcoins slow down. </figcaption></figure>
Stockmoney Lizards marks this price movement as the beginning of the &#8220;final cycle pump&#8221; and expects the cycle top around September to October 2025 between $200,000 and $260,000.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a>: The Final Cycle Pump Begins We are entering what could be the final pump of this Bitcoin cycle. The cycle top is expected around September to October 2025. My personal price target for Bitcoin is between $200,000 and $260,000. Legend: Here, you can see the last three… <a href="https://t.co/f7BTzM8YyM">pic.twitter.com/f7BTzM8YyM</a>
&mdash; Stockmoney Lizards (@StockmoneyL) <a href="https://twitter.com/StockmoneyL/status/1836835839340597600?ref_src=twsrc%5Etfw">September 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40932192/trump-pays-up-for-smash-burgers-and-diet-cokes-with-bitcoin-during-new-york-campaign-halt-">Trump Pays Up For Smash Burgers And Diet Cokes With Bitcoin During New York Campaign Halt — Move Hailed As &#8216;One Of The Most Historic Transactions&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$POPCAT

$SEI

$SHIB

$SOL

$WIF

Bitcoin, Ethereum, Dogecoin Surge: Has The 'Final Cycle Pump' Really Started?

Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors

Truist Financial analyst Joon Lee maintained a Buy rating on Adverum Biotechnologies (ADVM – Research Report) today. The company's shares closed ye...

Truist Financial Keeps Their Buy Rating on Adverum Biotechnologies (ADVM)

Adverum Biotechnologies GAAP EPS of -$0.89 beats by $0.58

TD Cowen analyst Joseph Thome has maintained their bullish stance on ADVM stock, giving a Buy rating on August 2. Joseph Thome has given his Buy ra...

Buy Rating for Adverum Biotechnologies Based on Promising Ixo-Vec Therapy and Strategic Growth Opportunities

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Adverum Biotechnologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/advm-stock-quote/">ADVM</a>) just reported results for the second quarter of 2024.<ul><li>Adverum Biotechnologies reported earnings per share of -89 cents. This was above the analyst estimate for EPS of -$1.45.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/advm-stock-earnings-adverum-biotechnologies-for-q2-of-2024/">ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q2 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adverum Biotechnologies (ADVM – Research Report), As...

Analysts' Top Healthcare Picks: Adverum Biotechnologies (ADVM), Astria Therapeutics (ATXS)

Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on Adverum Biotechnologies (ADVM – Research Report), with a price target of $30...

Adverum Biotechnologies' Ixo-vec Shows Promise in Wet AMD Treatment: Analyst Reiterates Buy Rating and $30 Price Target

RBC Capital analyst Luca Issi maintained a Hold rating on Adverum Biotechnologies (ADVM – Research Report) yesterday and set a price target of $12....

Adverum Biotechnologies (ADVM) Receives a Hold from RBC Capital

In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on Adverum Biotechnologies (ADVM – Research Report), with a...

Adverum Biotechnologies (ADVM) Receives a Buy from Oppenheimer

Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on ADVM stock, giving a Buy rating on August 13. Graig Suvannavejh ...

Adverum Biotechnologies: A Strong Buy on Promising Gene Therapy Prospects and Financial Stability

ATXS

EYPT

MSCLF

OCUL

REGN

RGNX

Health Care

Press Releases

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors

Adverum Biotechnologies to Participate in TD Cowen's Genetic Medicines & RNA Summit

Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Adverum Biotechnologies

Adverum Biotechnologies (ADVM) Forecast

Adverum Biotechnologies (NASDAQ:ADVM) Stock, Quote.Headers.trade-ideas